GlassScriptPhysician profile
Bela Glantsman
NPI 1750347803
$3,685.77
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $733 · 2020: $889 · 2021: $1,133 · 2022: $836 · 2023: $66.07 · 2024: $27.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $93.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $93.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $930.24 | 2019-2024 | |
| Amarin Pharma, INC. | $321.33 | 2019-2021 | |
| Allergan, INC. | $171.00 | 2019-2020 | |
| Pfizer INC. | $170.46 | 2020-2022 | |
| Galderma Laboratories, L.P. | $167.40 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $152.54 | 2019-2022 | |
| Philips North America LLC | $142.47 | 2019-2023 | |
| Novo Nordisk INC | $141.22 | 2020-2023 | Rybelsus, Ozempic |
| Vivus LLC | $135.53 | 2020-2022 | |
| Amgen INC. | $131.01 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.65 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $124.29 | 2020-2021 | |
| Glaxosmithkline, LLC. | $123.04 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $121.55 | 2021 | |
| Lilly USA, LLC | $113.05 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $102.23 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.81 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $79.74 | 2020-2022 | |
| Hikma Pharmaceuticals USA | $50.81 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $48.01 | 2020-2021 | |
| Astellas Pharma US INC | $30.59 | 2021 | |
| Eyevance Pharmaceuticals LLC | $29.81 | 2021 | |
| Esperion Therapeutics, INC. | $29.49 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $26.97 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.17 | 2022 | |
| Janssen Pharmaceuticals, INC | $20.36 | 2020 | |
| Bioventus LLC | $18.53 | 2019 | |
| Seqirus USA INC | $18.09 | 2020 | |
| Phadia US INC. | $15.92 | 2019 | |
| Xeris Pharmaceuticals, INC. | $15.10 | 2022 | |
| Currax Pharmaceuticals LLC | $13.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bela Glantsman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.